Sponsors (2)
The bill strengthens FDA and customs authority to keep misbranded or risky products and those tied to debarred actors out of the U.S. market, improving consumer safety and industry accountability, but it raises compliance costs, legal exposure for businesses, potential taxpayer-funded enforcement expenses, and litigation risk from drafting ambiguity.
Consumers (including patients with chronic conditions and uninsured people) gain stronger protection because FDA and customs can detain, refuse admission, or seize products marketed as dietary supplements that do not meet the statutory definition, reducing the chance unsafe or misbranded products reach the U.S. market.
Federal and local public health authorities (FDA, customs, state and local governments) receive clearer legal grounds to act at the border on noncompliant imports, improving the enforceability of supplement standards.
Consumers and the market benefit from improved industry accountability because the bill reduces the likelihood that products involving debarred persons reach consumers, incentivizing safer sourcing and supplier vetting.
Small manufacturers and importers face higher compliance risk and potential financial losses because products reclassified or seized at the border can result in lost inventory and disrupted sales.
Companies (including small businesses and government contractors) could face legal penalties or debarment exposure for supply‑chain ties to debarred persons even if the company lacked knowledge, increasing legal risk and compliance burden.
The drafting ambiguity from the incomplete insertion into the statute could create legal uncertainty and trigger litigation over enforcement scope, imposing costs and delay for regulated firms and federal employees.
Based on analysis of 2 sections of legislative text.
Prohibits interstate sale/import of products marketed as dietary supplements that don't meet the statutory definition and bars supplements handled with assistance of debarred persons; adds customs refusal and FDA seizure grounds.
Official title: Amend the Federal Food, Drug, and Cosmetic Act to establish new prohibited acts relating to dietary supplements.
Introduced February 5, 2026 by Richard Joseph Durbin · Last progress February 5, 2026
Prohibits interstate sale and importation of products marketed as dietary supplements if they do not meet the statutory definition of a “dietary supplement,” and bars supplements prepared, packed, or held with the assistance of a person debarred under federal law. It adds those violations as grounds for U.S. Customs refusal of admission and for FDA seizure authority, expanding enforcement tools against misbranded or improperly produced supplement products. The changes primarily affect supplement manufacturers, distributors, importers, and any debarred individuals or firms involved in supplement production or handling.